Edward J Dulac Iii Fate Therapeutics Inc (FATE) insider trading activity

Edward J Dulac Iii is Chief Financial Officer of FATE THERAPEUTICS INC. Currently has a direct ownership of 101,479 shares of FATE, which is worth approximately $170,484. The most recent transaction as insider was on Mar 04, 2024, when has been sold 2,447 shares (Common Stock) at a price of $7.77 per share, resulting in proceeds of $19,013. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 101K

0% 3M change

13.99% 12M change

Total Value Held $170,484

Edward J Dulac III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2024	SELL Open market or private sale	$19,013 $7.77 p/Share	2,447 Reduced 2.35%	101,479 Common Stock
Jan 29 2024	SELL Open market or private sale	$9,245 $5.0 p/Share	1,849 Reduced 1.75%	103,926 Common Stock
Jan 09 2024	SELL Open market or private sale	$30,712 $4.37 p/Share	7,028 Reduced 6.23%	105,775 Common Stock
Jan 02 2024	SELL Open market or private sale	$18,966 $3.66 p/Share	5,182 Reduced 4.39%	112,803 Common Stock
Dec 18 2023	SELL Open market or private sale	$5,547 $3.5 p/Share	1,585 Reduced 1.33%	117,985 Common Stock
Aug 18 2023	SELL Open market or private sale	$13,210 $2.8 p/Share	4,718 Reduced 3.8%	119,570 Common Stock
Jul 05 2023	SELL Open market or private sale	$25,029 $4.83 p/Share	5,182 Reduced 4.0%	124,288 Common Stock
Jan 10 2023	SELL Open market or private sale	$38,414 $5.24 p/Share	7,331 Reduced 5.36%	129,470 Common Stock
Aug 18 2022	SELL Open market or private sale	$154,461 $30.08 p/Share	5,135 Reduced 3.62%	136,801 Common Stock
Jan 25 2022	BUY Grant, award, or other acquisition	-	33,302 Added 19.0%	141,936 Common Stock
Jan 11 2022	SELL Open market or private sale	$86,217 $48.71 p/Share	1,770 Reduced 1.6%	108,634 Common Stock
Dec 20 2021	SELL Open market or private sale	$958,620 $60.0 p/Share	15,977 Reduced 12.64%	110,404 Common Stock
Dec 20 2021	BUY Exercise of conversion of derivative security	$512,802 $35.52 p/Share	14,437 Added 10.25%	126,381 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	59,540 Added 34.72%	111,944 Common Stock
Sep 28 2021	SELL Open market or private sale	$1,216,834 $62.53 p/Share	19,460 Reduced 27.08%	52,404 Common Stock
Sep 28 2021	BUY Exercise of conversion of derivative security	$615,384 $35.52 p/Share	17,325 Added 19.43%	71,864 Common Stock
Aug 19 2021	SELL Open market or private sale	$308,665 $88.85 p/Share	3,474 Reduced 5.99%	54,539 Common Stock
Jan 20 2021	BUY Grant, award, or other acquisition	-	18,013 Added 23.69%	58,013 Common Stock

Also insider at

NTLA

Intellia Therapeutics, Inc. Healthcare

EVP, Chief Financial Officer

EJD